OPKO Health Corporate Presentation March 2024

OPKO Health presents its diverse global portfolio strategy focused on growing its commercial HGH franchise and specialty testing segments. The company highlights NGENLA, a long-acting growth hormone therapy partnered with Pfizer in a $5.5B market, alongside next-generation multispecific antibody programs in immunology and infectious disease developed with BARDA, Merck, and NIH support.